Abeona Therapeutics (ABEO) 10-Q 12 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 07, 2019
Document and Entity Information
Entity Registrant Name	ABEONA THERAPEUTICS INC.
Entity Central Index Key	0000318306
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		51,154,395
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 47,923,000	$ 18,750,000
Short-term investments		66,218,000
Receivables	15,000	81,000
Prepaid expenses and other current assets	1,654,000	3,802,000
Total current assets	49,592,000	88,851,000
Property and equipment, net	13,814,000	9,443,000
Right-of-use lease assets	8,286,000
Licensed technology, net	37,471,000	43,042,000
Goodwill	32,466,000	32,466,000
Other assets and restricted cash	1,143,000	597,000
Total assets	142,772,000	174,399,000
Current liabilities:
Accounts payable	2,714,000	6,122,000
Accrued expenses	5,532,000	3,936,000
Current portion of lease liability	1,696,000
Current portion of payable to licensor	10,000,000	10,000,000
Deferred revenue	296,000	296,000
Total current liabilities	20,238,000	20,354,000
Long-term lease liabilities	6,482,000
Payable to licensor, net of current portion	20,000,000	20,000,000
Total liabilities	46,720,000	40,354,000
Commitments and contingencies
Stockholders' equity:
Common stock - $0.01 par value; authorized 200,000,000 shares; issued and outstanding 51,054,395 at September 30, 2019; issued and outstanding 47,944,486 at December 31, 2018	511,000	479,000
Additional paid-in capital	565,580,000	543,754,000
Accumulated deficit	(470,039,000)	(410,188,000)
Total stockholders' equity	96,052,000	134,045,000
Total liabilities and stockholders' equity	$ 142,772,000	$ 174,399,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common Stock, par value	$ 0.01	$ 0.01
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	51,054,395	47,944,486
Common Stock, shares outstanding	51,054,395	47,944,486

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues:
Total revenues		$ 1,709,000		$ 2,516,000
Expenses:
Research and development	10,917,000	13,150,000	38,961,000	29,228,000
General and administrative	4,700,000	4,970,000	15,971,000	12,475,000
Depreciation and amortization	2,032,000	505,000	5,747,000	969,000
Total expenses	17,649,000	18,625,000	60,679,000	42,672,000
Loss from operations	(17,649,000)	(16,916,000)	(60,679,000)	(40,156,000)
Interest and miscellaneous income	277,000	500,000	828,000	973,000
Interest and other expense		(3,000)		(9,000)
Net loss	$ (17,372,000)	$ (16,419,000)	$ (59,851,000)	$ (39,192,000)
Basic and diluted loss per common share	$ (0.35)	$ (0.34)	$ (1.22)	$ (0.83)
Weighted average number of common shares outstanding - basic and diluted	49,721,753	47,794,394	48,883,883	47,388,833
Foundation Revenues [Member]
Revenues:
Total revenues		$ 1,687,000		$ 2,427,000
Royalties [Member]
Revenues:
Total revenues		$ 22,000		$ 89,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]	Total
Beginning balance at Dec. 31, 2017	$ 469,000	$ 529,421,000	$ (359,792,000)	$ 170,098,000
Beginning balance, shares at Dec. 31, 2017	46,888,108
Cumulative effect adjustment of ASC 606 on January 1, 2018			6,275,000	6,275,000
Stock-based compensation expense		1,900,000		1,900,000
Restricted stock-based compensation expense		172,000		172,000
Common stock issued for cash exercise of options	$ 3,000	1,682,000		1,685,000
Common stock issued for cash exercise of options, shares	267,196
Common stock issued for exercise of $5.00 warrants		144,000		144,000
Common stock issued for exercise of $5.00 warrants, shares	28,874
Common stock issued for cashless warrant exercises
Common stock issued for cashless warrant exercises, shares	48,762
Net loss			(10,530,000)	(10,530,000)
Ending balance at Mar. 31, 2018	$ 472,000	533,319,000	(364,047,000)	169,744,000
Ending balance, shares at Mar. 31, 2018	47,232,940
Beginning balance at Dec. 31, 2017	$ 469,000	529,421,000	(359,792,000)	170,098,000
Beginning balance, shares at Dec. 31, 2017	46,888,108
Net loss				(39,192,000)
Ending balance at Sep. 30, 2018	$ 480,000	542,476,000	(392,709,000)	150,247,000
Ending balance, shares at Sep. 30, 2018	47,944,486
Beginning balance at Mar. 31, 2018	$ 472,000	533,319,000	(364,047,000)	169,744,000
Beginning balance, shares at Mar. 31, 2018	47,232,940
Stock-based compensation expense		2,673,000		2,673,000
Restricted stock-based compensation expense		172,000		172,000
Common stock issued for cash exercise of options	$ 1,000	480,000		481,000
Common stock issued for cash exercise of options, shares	76,956
Common stock issued for exercise of $5.00 warrants		89,000		89,000
Common stock issued for exercise of $5.00 warrants, shares	17,889
Net loss			(12,243,000)	(12,243,000)
Ending balance at Jun. 30, 2018	$ 473,000	536,733,000	(376,290,000)	160,916,000
Ending balance, shares at Jun. 30, 2018	47,327,785
Stock-based compensation expense		2,499,000		2,499,000
Restricted stock-based compensation expense		172,000		172,000
Common stock issued for cash exercise of options	$ 1,000	78,000		79,000
Common stock issued for cash exercise of options, shares	16,701
Common stock issued for exercise of $5.00 warrants	$ 6,000	2,994,000		3,000,000
Common stock issued for exercise of $5.00 warrants, shares	600,000
Net loss			(16,419,000)	(16,419,000)
Ending balance at Sep. 30, 2018	$ 480,000	542,476,000	(392,709,000)	150,247,000
Ending balance, shares at Sep. 30, 2018	47,944,486
Beginning balance at Dec. 31, 2018	$ 479,000	543,754,000	(410,188,000)	134,045,000
Beginning balance, shares at Dec. 31, 2018	47,944,486
Stock-based compensation expense		2,103,000		2,103,000
Restricted stock-based compensation expense		172,000		172,000
Common stock issued for cash exercise of options		28,000		28,000
Common stock issued for cash exercise of options, shares	5,208
Net loss			(18,555,000)	(18,555,000)
Ending balance at Mar. 31, 2019	$ 479,000	546,057,000	(428,743,000)	117,793,000
Ending balance, shares at Mar. 31, 2019	47,949,694
Beginning balance at Dec. 31, 2018	$ 479,000	543,754,000	(410,188,000)	134,045,000
Beginning balance, shares at Dec. 31, 2018	47,944,486
Net loss				(59,851,000)
Ending balance at Sep. 30, 2019	$ 511,000	565,580,000	(470,039,000)	96,052,000
Ending balance, shares at Sep. 30, 2019	51,054,395
Beginning balance at Mar. 31, 2019	$ 479,000	546,057,000	(428,743,000)	117,793,000
Beginning balance, shares at Mar. 31, 2019	47,949,694
Stock-based compensation expense		1,678,000		1,678,000
Restricted stock-based compensation expense		78,000		78,000
Common stock issued for cash exercise of options	$ 1,000	384,000		385,000
Common stock issued for cash exercise of options, shares	91,126
Common stock issued for cash under open market sale agreement	$ 17,000	12,605,000		12,622,000
Common stock issued for cash under open market sale agreement, shares	1,658,677
Shares returned in connection with arbitration ruling on licensing agreement	$ (5,000)	(1,467,000)		(1,472,000)
Shares returned in connection with arbitration ruling on licensing agreement, shares	(450,000)
Net loss			(23,924,000)	(23,924,000)
Ending balance at Jun. 30, 2019	$ 492,000	559,335,000	(452,667,000)	107,160,000
Ending balance, shares at Jun. 30, 2019	49,249,497
Stock-based compensation expense		1,826,000		1,826,000
Restricted stock-based compensation expense		98,000		98,000
Common stock issued for restricted share awards	$ 4,000	(4,000)
Common stock issued for restricted share awards, shares	376,625
Net loss			(17,372,000)	(17,372,000)
Ending balance at Sep. 30, 2019	$ 511,000	$ 565,580,000	$ (470,039,000)	$ 96,052,000
Ending balance, shares at Sep. 30, 2019	51,054,395

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Statement of Stockholders' Equity [Abstract]
Class of warrant or right, exercise price of warrants or rights	$ 5	$ 5	$ 5	$ 5

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (17,372,000)	$ (16,419,000)	$ (59,851,000)	$ (39,192,000)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	2,032,000	505,000	5,747,000	969,000
Stock option-based compensation expense	1,826,000	2,499,000	5,607,000	7,072,000
Restricted stock-based compensation expense			348,000	516,000
Accretion and interest on short-term investments			(1,090,000)
Non-cash loss on arbitration ruling on licensing agreement			367,000
Change in operating assets and liabilities:
Receivables			66,000	(245,000)
Prepaid expenses and other current assets			2,148,000	760,000
Right-of-use lease assets and other assets			623,000	40,000
Accounts payable, accrued expenses and lease liabilities			(2,539,000)	7,936,000
Net cash used in operating activities			(48,574,000)	(22,144,000)
Cash flows from investing activities:
Capital expenditures			(6,187,000)	(8,580,000)
Acquisition of licensed technology			(199,000)
Purchases of short-term investments				(94,991,000)
Proceeds from maturities of short-term investments			67,308,000	16,366,000
Net cash provided by (used in) investing activities			60,922,000	(87,205,000)
Cash flows from financing activities:
Proceeds from open market sales of common stock			16,962,000
Proceeds from exercise of $5.00 warrants				3,233,000
Proceeds from exercise of stock options			413,000	2,245,000
Net cash provided by financing activities			17,375,000	5,478,000
Net increase (decrease) in cash, cash equivalents and restricted cash			29,723,000	(103,871,000)
Cash, cash equivalents and restricted cash at beginning of period			19,310,000	138,030,000
Cash, cash equivalents and restricted cash at end of period	49,033,000	34,159,000	49,033,000	34,159,000
Supplemental cash flow information:
Cash and cash equivalents	47,923,000	33,599,000	47,923,000	33,599,000
Restricted cash	1,110,000	560,000	1,110,000	560,000
Total cash, cash equivalents and restricted cash	$ 49,033,000	$ 34,159,000	49,033,000	34,159,000
Shares returned in connection with arbitration ruling on licensing agreement			1,472,000
Cash paid for interest				$ 9,000

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Statement of Cash Flows [Abstract]
Class of warrant or right, exercise price of warrants or rights	$ 5	$ 5	$ 5	$ 5

Nature of Operations and Signif

Nature of Operations and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Significant Accounting Policies	NOTE 1 – NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES Background Abeona Therapeutics Inc., a Delaware corporation (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”), is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic diseases. Our lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (“RDEB”); ABO-102, an adeno-associated virus (“AAV”)-based gene therapy for Sanfilippo syndrome type A (“MPS IIIA”); and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B (“MPS IIIB”). We also are developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-5OX for the treatment of retinal diseases. In addition, we are developing next-generation AAV-based gene therapy though our novel AIM™ capsid platform and internal AAV vector research programs. Our efforts since inception have been principally devoted to research and development, resulting in significant losses. Basis of Presentation The condensed consolidated balance sheet as of September 30, 2019, the condensed consolidated statements of operations and stockholders’ equity for the three and nine months ended September 30, 2019 and 2018 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2019 and 2018, were prepared by management without audit. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, except as otherwise disclosed, necessary for the fair presentation of the financial position, results of operations, and changes in financial position for such periods, have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted. These interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended December 31, 2018. The results of operations for the periods ended September 30, 2019 are not necessarily indicative of the operating results that may be expected for a full year. The condensed consolidated balance sheet as of December 31, 2018 contains financial information taken from the audited Abeona consolidated financial statements as of that date. As of September 30, 2019, we had 6,697,980 options and 1,820,686 warrants that were not included in the EPS calculation as their effect would be antidilutive. As of September 30, 2018, we had 5,999,544 options and 2,220,687 warrants that were not included in the earnings per share calculation as their effect would be antidilutive. Effective January 1, 2018, we adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers Uses and Sources of Liquidity The financial statements have been prepared on a going concern basis, which assumes the Company will have sufficient cash to pay its operating expenses, as and when they become payable, for a period of at least 12 months from the date the financial report was issued. Therefore, we believe it is appropriate to prepare the financial statements on a going concern basis. As of September 30, 2019, we had cash, cash equivalents and short-term investments of $47.9 million and net assets of $96.1 million. For the nine months ended September 30, 2019, we had cash outflows from operations of $48.6 million. In early 2019, the Company implemented a multi-faceted program to seek sufficient liquidity through at least the end of 2020. This program considered the possibility of accessing additional equity funding from current or new stockholders, out-licensing technology and/or other assets, deferring and/or eliminating planned expenditures, restructuring operations and/or reducing headcount and sales of assets. In September 2019, the Company announced that it has retained Jefferies LLC as its financial advisor to assist with the review of strategic options focused on advancing the Company’s mission and maximizing stockholder value. In an effort to unlock potential additional value, the Company initiated this more formal process to explore a broad range of strategic alternatives including but not limited to the partnering of its various clinical and pre-clinical programs, or a sale or merger of the Company.

New Accounting Standard Impleme

New Accounting Standard Implemented	9 Months Ended
	Sep. 30, 2019
Accounting Changes and Error Corrections [Abstract]
New Accounting Standard Implemented	NOTE 2 – NEW ACCOUNTING STANDARD IMPLEMENTED In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases Additional information and disclosures required by this new standard are contained in Note 8.

Short-Term Investments

Short-Term Investments	9 Months Ended
	Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Short-Term Investments	NOTE 3 – SHORT-TERM INVESTMENTS The following table summarizes the available-for-sale investments held: Description September 30, 2019 December 31, 2018 U.S. government and agency securities and treasuries $ - $ 66,218,000 The amortized cost of the available-for-sale investments is adjusted for amortization of premiums and accretion of discounts to maturity. There were no material realized gains or losses recognized on the sale or maturity of available-for-sale investments during the three and nine months ended September 30, 2019 and 2018.

Licensed Technology

Licensed Technology	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Licensed Technology	NOTE 4 – LICENSED TECHNOLOGY On November 4, 2018, we entered into a license agreement with REGENXBIO to obtain rights to an exclusive worldwide license (subject to certain non-exclusive rights previously granted for MPS IIIA), with rights to sublicense, to REGENXBIO’s NAV AAV9 vector for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 Disease and CLN3 Disease. In return for these rights, REGENXBIO received a guaranteed $20 million upfront payment, $10 million of which was paid on signing of the agreement on November 4, 2018 and $10 million of which was originally required under the agreement to be paid by November 4, 2019. In addition, REGENXBIO will receive a total of $100 million in annual fees, payable upon the second through sixth anniversaries of the agreement, $20 million of which is guaranteed and payable on November 4, 2020. REGENXBIO is also eligible to receive potential commercial milestone payments of up to $60 million as well as royalties payable in the low double digits to low teens on net sales of products incorporating the licensed intellectual property. The license is amortized over the life of the patent of eight years. On November 1, 2019, we entered into an amendment of the original license agreement. The amended agreement replaced the $10 million payment due on November 4, 2019 with a $3 million payment due on November 4, 2019 and an additional $8 million payment due on April 1, 2020. On August 3, 2016, we announced that we entered into an agreement (the “EB Agreement”) with EB Research Partnership (“EBRP”) and Epidermolysis Bullosa Medical Research Foundation (“EBMRF”) to collaborate on gene therapy treatments for EB. The EB Agreement became effective August 3, 2016 on the execution of two licensing agreements with The Board of Trustees of Leland Stanford Junior University (“Stanford”). On August 3, 2016, we recorded the issuance of 375,000 of our common shares to each of EBRP and EBMRF and recorded licensed technology of $2.45 million, which was being amortized over 20 years. In connection with an arbitration proceeding relating to the EB Agreement, on May 15, 2019, the arbitrator issued a decision in favor of the Company requiring the Company to cancel any and all shares of its common stock issued to EBRP and EBMRF that were still in their possession. As a result, we have recorded the return of 450,000 shares of our common stock and the reversal of the licensed technology from our financial statements. The net of these transactions resulted in a non-cash charge to expense of $367,000 recorded during the nine months ended September 30, 2019. On May 15, 2015, we acquired Abeona Therapeutics LLC, which had an exclusive license through Nationwide Children’s Hospital to the AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. The license is amortized over the life of the license of 20 years. Licensed technology consists of the following: September 30, 2019 December 31, 2018 Licensed technology $ 42,606,000 $ 44,859,000 Less accumulated amortization 5,135,000 1,817,000 Licensed technology, net $ 37,471,000 $ 43,042,000 The aggregate estimated amortization expense for intangible assets remaining as of September 30, 2019 is as follows: 2019, remainder $ 1,293,000 2020 5,167,000 2021 5,167,000 2022 5,167,000 2023 5,167,000 Thereafter 15,510,000 Total $ 37,471,000

Restricted Cash

Restricted Cash	9 Months Ended
	Sep. 30, 2019
Restricted Cash [Abstract]
Restricted Cash	NOTE 5 – RESTRICTED CASH Restricted cash, which is reported within other assets and restricted cash on the condensed consolidated balance sheets, consists of cash and cash equivalents held as collateral for a corporate credit card and office space in New York. As such, the cash and cash equivalents are restricted in use.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE 6 – FAIR VALUE MEASUREMENTS We calculate the fair value of our assets and liabilities that qualify as financial instruments and include additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of these financial instruments. The estimated fair value of receivables, prepaid expenses, other assets, accounts payable, accrued expenses, payable to licensor and deferred revenue approximate their carrying amounts due to the relatively short maturity of these instruments. U.S. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. This guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: ● Level 1 – Quoted prices in active markets for identical assets or liabilities. ● Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. ● Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs. The guidance requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. We have segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually) into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. Financial assets and liabilities measured at fair value on a recurring and non-recurring basis as of September 30, 2019 and December 31, 2018 are summarized below: Description September 30, 2019 Level 1 Level 2 Level 3 Total Gains/(Losses) Non-recurring Assets: Licensed technology, net $ 37,471,000 $ - $ - $ 37,471,000 $ (367,000 ) Goodwill 32,466,000 - - 32,466,000 - Description December 31, 2018 Level 1 Level 2 Level 3 Total Gains/(Losses) Recurring Assets: Short-term investments $ 66,218,000 $ - $ 66,218,000 $ - $ - Non-recurring Assets: Licensed technology, net $ 43,042,000 $ - $ - $ 43,042,000 $ - Goodwill 32,466,000 - - 32,466,000 -

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	NOTE 7 – STOCK-BASED COMPENSATION The following table summarizes option-based compensation expense for the three and nine months ended September 30, 2019 and 2018: For the three months ended September 30, For the nine months ended September 30, 2019 2018 2019 2018 Research and development $ 972,000 $ 1,012,000 $ 3,013,000 $ 2,756,000 General and administrative 854,000 1,487,000 2,594,000 4,316,000 Stock-based compensation expense included in operating expense 1,826,000 2,499,000 5,607,000 7,072,000 Total stock-based compensation expense 1,826,000 2,499,000 5,607,000 7,072,000 Tax benefit - - - - Stock-based compensation expense, net of tax $ 1,826,000 $ 2,499,000 $ 5,607,000 $ 7,072,000 We estimate the fair value of each option award on the date of grant using the Black-Scholes option valuation model. We then recognize the grant date fair value of each option as compensation expense ratably using the straight-line attribution method over the service period (generally the vesting period). The Black-Scholes model incorporates the following assumptions: ● Expected volatility – we estimate the volatility of our share price at the date of grant using a “look-back” period which coincides with the expected term, defined below. We believe using a “look-back” period which coincides with the expected term is the most appropriate measure for determining expected volatility. ● Expected term – we estimate the expected term using the “simplified” method, as outlined in Staff Accounting Bulletin No. 107, “Share-Based Payment.” ● Risk-free interest rate – we estimate the risk-free interest rate using the U.S. Treasury yield curve for periods equal to the expected term of the options in effect at the time of grant. ● Dividends – we use an expected dividend yield of zero because we have not declared or paid a cash dividend, nor do we have any plans to declare a dividend. We used the following weighted-average assumptions to estimate the fair value of the options granted for the periods indicated: For the three months ended September 30, For the nine months ended September 30, 2019 2018 2019 2018 Expected volatility 103 % 109 % 108 % 109 % Expected term 6.25 years 5.00 years 5.09 years 5.00 years Risk-free interest rate 1.83 % 2.78 % 2.21 % 2.54 % Expected dividend yield 0 % 0 % 0 % 0 % The following table summarizes the options granted for the periods indicated: For the three months ended September 30, For the nine months ended September 30, 2019 2018 2019 2018 Options granted 105,600 157,000 1,490,490 1,026,800 Weighted-average: Exercise price $ 2.58 $ 14.45 $ 6.53 $ 14.38 Grant date fair value $ 2.09 $ 11.44 $ 5.14 $ 11.36 The following table summarizes restricted common stock-based compensation expense for the three and nine months ended September 30, 2019 and 2018: For the three months ended September 30, For the nine months ended September 30, 2019 2018 2019 2018 Research and development $ 66,000 $ - $ 66,000 $ - General and administrative 32,000 172,000 282,000 516,000 Stock-based compensation expense included in operating expense 98,000 172,000 348,000 516,000 Total stock-based compensation expense 98,000 172,000 348,000 516,000 Tax benefit - - - - Stock-based compensation expense, net of tax $ 98,000 $ 172,000 $ 348,000 $ 516,000 We granted 376,625 shares of restricted common stock to employees during the three and nine months ended September 30, 2019. We did not grant any restricted common stock to employees during the three and nine months ended September 30, 2018.

Operating Leases

Operating Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Operating Leases	NOTE 8 – OPERATING LEASES We lease space under non-cancelable operating leases for manufacturing and laboratory facilities and administrative offices in Cleveland as well as administrative offices in New York. The leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants or contingent rent provisions. Our leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs) which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. We also lease office space in Madrid, Spain as well as certain office equipment under operating leases, which have a non-cancelable lease term of less than one year and therefore, we have elected the practical expedient to exclude these short-term leases from our right-of-use assets and lease liabilities. Most leases include one or more options to renew. The exercise of lease renewal options is typically at our sole discretion; therefore, the majority of renewals to extend the lease terms are not included in our right-of-use assets and lease liabilities as they are not reasonably certain of exercise. We regularly evaluate the renewal options and when they are reasonably certain of exercise, we include the renewal period in our lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments. Components of lease cost are as follows: Three months ended September 30, 2019 Nine months ended September 30, 2019 Operating lease cost $ 434,000 $ 1,157,000 Variable lease cost $ 82,000 $ 241,000 Short-term lease cost $ 32,000 $ 113,000 The following table presents information about the amount and timing of cash flows arising from operating leases as of September 30, 2019: Maturity of lease liabilities: 2019, remainder $ 422,000 2020 1,699,000 2021 1,713,000 2022 1,727,000 2023 1,741,000 Thereafter 3,667,000 Total undiscounted operating lease payments 10,969,000 Less: imputed interest 2,791,000 Present value of operating lease liabilities $ 8,178,000 Balance sheet classification: Current portion of lease liability $ 1,696,000 Long-term lease liability 6,482,000 Total operating lease liabilities $ 8,178,000 Other information: Weighted-average remaining lease term for operating leases 76 months Weighted-average discount rate for operating leases 9.6 %

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9 – COMMITMENTS AND CONTINGENCIES On January 18, 2018, William Mahon, a Company stockholder, served a demand upon the Company’s board of directors (the “Board”) pursuant to Section 220 of the Delaware General Corporation Law (the “Demand”) seeking to inspect certain of the Company’s books and records. Generally, the Demand’s stated purpose was to investigate allegedly excessive compensation awarded to non-employee Board members for the fiscal years 2015–2017. The Board denied the allegations in the Demand, and agreed to provide limited books and records to Mahon. On September 17, 2018, another Company stockholder, Francisco Dos Ramos, filed a stockholder derivative complaint in the Delaware Chancery Court (the “Dos Ramos Action”) against Steven Rouhandeh, Frank Carsten Thiel, Mark Alvino, Stefano Buono, Stephen Howell, Richard Van Duyne, and Todd Wider as defendants, and the Company as nominal defendant (the “Dos Ramos Defendants”). Dos Ramos generally alleged that the Board breached its fiduciary duties, were unjustly enriched, and committed corporate waste by approving allegedly excessive compensation to non-employee Board members for the fiscal years 2015–2017. Dos Ramos generally sought disgorgement of the allegedly improper payments to the Board, money damages, an order requiring corporate governance reforms, costs and attorneys’ fees. On November 28, 2018, Mahon filed a stockholder derivative complaint (the “Mahon Action”) in the United States District Court for the District of Delaware (the “District Court”) against Mark Ahn, Mark Alvino, Jeffrey Davis, Stephen Howell, Todd Wider, and Steven Rouhandeh, as defendants, and the Company as a nominal defendant (“Mahon Defendants”). The allegations in the Mahon Action were substantially similar to those set forth in his Demand, as well as those in the Dos Ramos Action. Mahon generally sought the disgorgement of the allegedly improper payments to the Board, a constructive trust, money damages, costs and attorneys’ fees. On December 6, 2018, Mahon and the Mahon Defendants filed a joint motion for preliminary approval of settlement, along with a stipulation of settlement (the “Stipulation”) intending to settle all claims asserted in the Mahon Action. On January 8, 2019, the District Court approved the parties’ notice of settlement, enjoining all Company stockholders from commencing or further prosecuting any claims asserted in the Mahon Action, and scheduled a settlement approval hearing for May 1, 2019. On January 25, 2019, the Chancery Court entered an order staying the Dos Ramos Action until May 8, 2019—one week after the May 1, 2019 settlement hearing in the Mahon Action. On May 2, 2019 the District Court entered an Order and Final Judgment approving the Stipulation. On August 6, 2019, the plaintiff in the Dos Ramos Action filed a voluntary notice of dismissal. On August 7, 2019, the Chancery Court entered an order of dismissal. On October 22, 2018, EB Research Partnership, Inc. (“EBRP”) served upon the Company a Request for Arbitration (the “Request”), alleging that the Company was in breach of an Agreement executed in July 2016 (the “Agreement”) between and among the Company, EBRP, and Epidermolysis Bullosa Medical Research Foundation (“EBMRF” and together with EBRP, “Claimants”). EBRP alleged that Abeona had refused to lift trading restrictions on certain shares of Abeona common stock issued to EBRP, purportedly in breach of the Agreement. On November 21, 2018, the Company filed an action in the United States District Court for the Southern District of New York seeking a declaration that it was not required to arbitrate its dispute with EBRP on the basis that the Agreement was void for lack of consideration. On February 4, 2019, the court granted Claimants’ motion to compel arbitration. EBMRF was subsequently joined as a party to the arbitration. The parties submitted briefs to the arbitrator on March 18 and April 18, 2019. On May 15, 2019, the arbitrator issued a decision in favor of the Company (the “Final Award”). Specifically, the Final Award provides that the Agreement is void for lack of consideration; that Claimants fraudulently induced Abeona to enter into the Agreement; that Claimants cannot enforce the Agreement; that Claimants are not entitled to any relief under the Agreement; that, in view of their status as charitable organizations, Claimants would not be required to repay to Abeona the value of Abeona common stock they already sold; that the Company shall cancel any and all shares of Abeona common stock issued to Claimants that were still in Claimants’ possession; and that, as the losing parties, Claimants must bear the costs and expenses of the arbitration and Abeona’s costs and expenses.

Nature of Operations and Sign_2

Nature of Operations and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background	Background Abeona Therapeutics Inc., a Delaware corporation (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”), is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic diseases. Our lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (“RDEB”); ABO-102, an adeno-associated virus (“AAV”)-based gene therapy for Sanfilippo syndrome type A (“MPS IIIA”); and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B (“MPS IIIB”). We also are developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-5OX for the treatment of retinal diseases. In addition, we are developing next-generation AAV-based gene therapy though our novel AIM™ capsid platform and internal AAV vector research programs. Our efforts since inception have been principally devoted to research and development, resulting in significant losses.
Basis of Presentation	Basis of Presentation The condensed consolidated balance sheet as of September 30, 2019, the condensed consolidated statements of operations and stockholders’ equity for the three and nine months ended September 30, 2019 and 2018 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2019 and 2018, were prepared by management without audit. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, except as otherwise disclosed, necessary for the fair presentation of the financial position, results of operations, and changes in financial position for such periods, have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted. These interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended December 31, 2018. The results of operations for the periods ended September 30, 2019 are not necessarily indicative of the operating results that may be expected for a full year. The condensed consolidated balance sheet as of December 31, 2018 contains financial information taken from the audited Abeona consolidated financial statements as of that date. As of September 30, 2019, we had 6,697,980 options and 1,820,686 warrants that were not included in the EPS calculation as their effect would be antidilutive. As of September 30, 2018, we had 5,999,544 options and 2,220,687 warrants that were not included in the earnings per share calculation as their effect would be antidilutive. Effective January 1, 2018, we adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers
Uses and Sources of Liquidity	Uses and Sources of Liquidity The financial statements have been prepared on a going concern basis, which assumes the Company will have sufficient cash to pay its operating expenses, as and when they become payable, for a period of at least 12 months from the date the financial report was issued. Therefore, we believe it is appropriate to prepare the financial statements on a going concern basis. As of September 30, 2019, we had cash, cash equivalents and short-term investments of $47.9 million and net assets of $96.1 million. For the nine months ended September 30, 2019, we had cash outflows from operations of $48.6 million. In early 2019, the Company implemented a multi-faceted program to seek sufficient liquidity through at least the end of 2020. This program considered the possibility of accessing additional equity funding from current or new stockholders, out-licensing technology and/or other assets, deferring and/or eliminating planned expenditures, restructuring operations and/or reducing headcount and sales of assets. In September 2019, the Company announced that it has retained Jefferies LLC as its financial advisor to assist with the review of strategic options focused on advancing the Company’s mission and maximizing stockholder value. In an effort to unlock potential additional value, the Company initiated this more formal process to explore a broad range of strategic alternatives including but not limited to the partnering of its various clinical and pre-clinical programs, or a sale or merger of the Company.

Short-Term Investments (Tables)

Short-Term Investments (Tables)	9 Months Ended
	Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Schedule of Available-for-Sale Investments Held	The following table summarizes the available-for-sale investments held: Description September 30, 2019 December 31, 2018 U.S. government and agency securities and treasuries $ - $ 66,218,000

Licensed Technology (Tables)

Licensed Technology (Tables)	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Licensed Technology	Licensed technology consists of the following: September 30, 2019 December 31, 2018 Licensed technology $ 42,606,000 $ 44,859,000 Less accumulated amortization 5,135,000 1,817,000 Licensed technology, net $ 37,471,000 $ 43,042,000
Schedule of Amortization Expense for Intangible Assets	The aggregate estimated amortization expense for intangible assets remaining as of September 30, 2019 is as follows: 2019, remainder $ 1,293,000 2020 5,167,000 2021 5,167,000 2022 5,167,000 2023 5,167,000 Thereafter 15,510,000 Total $ 37,471,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring and Non-Recurring Basis	Financial assets and liabilities measured at fair value on a recurring and non-recurring basis as of September 30, 2019 and December 31, 2018 are summarized below: Description September 30, 2019 Level 1 Level 2 Level 3 Total Gains/(Losses) Non-recurring Assets: Licensed technology, net $ 37,471,000 $ - $ - $ 37,471,000 $ (367,000 ) Goodwill 32,466,000 - - 32,466,000 - Description December 31, 2018 Level 1 Level 2 Level 3 Total Gains/(Losses) Recurring Assets: Short-term investments $ 66,218,000 $ - $ 66,218,000 $ - $ - Non-recurring Assets: Licensed technology, net $ 43,042,000 $ - $ - $ 43,042,000 $ - Goodwill 32,466,000 - - 32,466,000 -

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Option-Based Compensation Expenses	The following table summarizes option-based compensation expense for the three and nine months ended September 30, 2019 and 2018: For the three months ended September 30, For the nine months ended September 30, 2019 2018 2019 2018 Research and development $ 972,000 $ 1,012,000 $ 3,013,000 $ 2,756,000 General and administrative 854,000 1,487,000 2,594,000 4,316,000 Stock-based compensation expense included in operating expense 1,826,000 2,499,000 5,607,000 7,072,000 Total stock-based compensation expense 1,826,000 2,499,000 5,607,000 7,072,000 Tax benefit - - - - Stock-based compensation expense, net of tax $ 1,826,000 $ 2,499,000 $ 5,607,000 $ 7,072,000
Schedule of Weighted-average Assumptions to Estimate the Fair Value of the Options Granted	We used the following weighted-average assumptions to estimate the fair value of the options granted for the periods indicated: For the three months ended September 30, For the nine months ended September 30, 2019 2018 2019 2018 Expected volatility 103 % 109 % 108 % 109 % Expected term 6.25 years 5.00 years 5.09 years 5.00 years Risk-free interest rate 1.83 % 2.78 % 2.21 % 2.54 % Expected dividend yield 0 % 0 % 0 % 0 %
Schedule of Options Granted	The following table summarizes the options granted for the periods indicated: For the three months ended September 30, For the nine months ended September 30, 2019 2018 2019 2018 Options granted 105,600 157,000 1,490,490 1,026,800 Weighted-average: Exercise price $ 2.58 $ 14.45 $ 6.53 $ 14.38 Grant date fair value $ 2.09 $ 11.44 $ 5.14 $ 11.36
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Option-Based Compensation Expenses	The following table summarizes restricted common stock-based compensation expense for the three and nine months ended September 30, 2019 and 2018: For the three months ended September 30, For the nine months ended September 30, 2019 2018 2019 2018 Research and development $ 66,000 $ - $ 66,000 $ - General and administrative 32,000 172,000 282,000 516,000 Stock-based compensation expense included in operating expense 98,000 172,000 348,000 516,000 Total stock-based compensation expense 98,000 172,000 348,000 516,000 Tax benefit - - - - Stock-based compensation expense, net of tax $ 98,000 $ 172,000 $ 348,000 $ 516,000

Operating Leases (Tables)

Operating Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Schedule of Components of Lease Cost	Components of lease cost are as follows: Three months ended September 30, 2019 Nine months ended September 30, 2019 Operating lease cost $ 434,000 $ 1,157,000 Variable lease cost $ 82,000 $ 241,000 Short-term lease cost $ 32,000 $ 113,000
Schedule of Supplemental Cash Flow Information Related to Leases	The following table presents information about the amount and timing of cash flows arising from operating leases as of September 30, 2019: Maturity of lease liabilities: 2019, remainder $ 422,000 2020 1,699,000 2021 1,713,000 2022 1,727,000 2023 1,741,000 Thereafter 3,667,000 Total undiscounted operating lease payments 10,969,000 Less: imputed interest 2,791,000 Present value of operating lease liabilities $ 8,178,000 Balance sheet classification: Current portion of lease liability $ 1,696,000 Long-term lease liability 6,482,000 Total operating lease liabilities $ 8,178,000 Other information: Weighted-average remaining lease term for operating leases 76 months Weighted-average discount rate for operating leases 9.6 %

Nature of Operations and Sign_3

Nature of Operations and Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Cash, cash equivalents and short-term investments			$ 47,900,000
Net assets			142,772,000		$ 174,399,000
Net cash used in operating activities			$ (48,574,000)	$ (22,144,000)
Accounting Standards Update 2014-09 [Member]
New accounting pronouncement, effect of change on operating results	$ 543,000	$ 2,067,000
New accounting pronouncement, effect of adoption, quantification	$ 543,000	$ 2,067,000
New accounting pronouncement, effect of change on diluted earnings per share	$ 0.01	$ 0.04
Options [Member]
Antidilutive securities excluded from computation of earnings per share, amount			6,697,980	5,999,544
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share, amount			1,820,686	2,220,687

New Accounting Standard Imple_2

New Accounting Standard Implemented (Details Narrative) - USD ($)	Sep. 30, 2019	Jan. 02, 2019	Dec. 31, 2018
Operating lease, right-of-use asset	$ 8,286,000
Operating lease, liability	$ 8,178,000
Accounting Standards Update 2016-02 [Member]
Operating lease, right-of-use asset		$ 8,900,000
Operating lease, liability		$ 8,900,000

Short-Term Investments - Schedu

Short-Term Investments - Schedule Of Available-for-sale Investments Held (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
U.S. goverment and agency securities and treasuries		$ 66,218,000

Licensed Technology (Details Na

Licensed Technology (Details Narrative)	May 15, 2019shares	Nov. 04, 2018USD ($)	Aug. 03, 2016USD ($)Integer	Aug. 03, 2016USD ($)shares	May 15, 2015	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Nov. 04, 2019USD ($)	Dec. 31, 2018USD ($)
Due to licensor current						$ 10,000,000		$ 10,000,000			$ 10,000,000
Value of licensed technology						37,471,000		37,471,000			$ 43,042,000
Shares returned in connection with arbitration ruling on licensing agreement (in shares) | shares	450,000
Non-cash loss on arbitration ruling on licensing agreement								367,000
Amortization of intangible assets						$ 1,293,000	$ 87,000	$ 3,931,000	$ 260,000
Abeona Therapeutics Llc [Member]
Finite-lived intangible asset, useful life					20 years
Eb Agreement [Member]
Finite-lived intangible asset, useful life			20 years
Number of license agreements research and development arrangements | Integer			2
Original License Agreements [Member]
License to be paid										$ 10,000,000
Amended Agreements [Member]
License to be paid										3,000,000
Amended Agreements [Member] | April 1 2020 [Member]
License to be paid										$ 8,000,000
REGENXBIO [Member] | Licensing Agreements [Member]
Guaranteed upfront payment		$ 20,000,000
Payment on Execution of Contracts		10,000,000
Due to licensor current		10,000,000
Annual fees		100,000,000
Guaranteed and payable		$ 20,000,000
Maturity date		Nov. 4, 2020
Royalties payments		$ 60,000,000
Finite-lived intangible asset, useful life		8 years
EBRP [Member] | Eb Agreement [Member]
Issuance of common shares | shares				375,000
Value of licensed technology			$ 2,450,000	$ 2,450,000
EBMRF [Member] | Eb Agreement [Member]
Issuance of common shares | shares				375,000
Value of licensed technology			$ 2,450,000	$ 2,450,000

Licensed Technology - Schedule

Licensed Technology - Schedule of Licensed Technology (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Licensed technology	$ 42,606,000	$ 44,859,000
Less accumulated amortization	5,135,000	1,817,000
Licensed technology, net	$ 37,471,000	$ 43,042,000

Licensed Technology - Schedul_2

Licensed Technology - Schedule of Amortization Expense For Intangible Assets (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
2019, remainder	$ 1,293,000
2020	5,167,000
2021	5,167,000
2022	5,167,000
2023	5,167,000
Thereafter	15,510,000
Total	$ 37,471,000	$ 43,042,000

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring and Non-Recurring Basis (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Licensed Technology Net [Member] | Fair Value Measurements Nonrecurring [Member]
Fair value disclosure of assets	$ 37,471,000	$ 43,042,000
Fair value disclosure of gain loss	(367,000)
Licensed Technology Net [Member] | Fair Value Measurements Recurring [Member] | Fair Value Inputs Level1 [Member]
Fair value disclosure of assets
Licensed Technology Net [Member] | Fair Value Measurements Recurring [Member] | Fair Value Inputs Level2 [Member]
Fair value disclosure of assets
Licensed Technology Net [Member] | Fair Value Measurements Recurring [Member] | Fair Value Inputs Level3 [Member]
Fair value disclosure of assets	37,471,000	43,042,000
Goodwill [Member] | Fair Value Measurements Nonrecurring [Member]
Fair value disclosure of assets	32,466,000	32,466,000
Fair value disclosure of gain loss
Goodwill [Member] | Fair Value Measurements Nonrecurring [Member] | Fair Value Inputs Level1 [Member]
Fair value disclosure of assets
Goodwill [Member] | Fair Value Measurements Nonrecurring [Member] | Fair Value Inputs Level2 [Member]
Fair value disclosure of assets
Goodwill [Member] | Fair Value Measurements Nonrecurring [Member] | Fair Value Inputs Level3 [Member]
Fair value disclosure of assets	$ 32,466,000	32,466,000
Short Term Investment [Member] | Fair Value Measurements Recurring [Member]
Fair value disclosure of assets		66,218,000
Fair value disclosure of gain loss
Short Term Investment [Member] | Fair Value Measurements Recurring [Member] | Fair Value Inputs Level1 [Member]
Fair value disclosure of assets
Short Term Investment [Member] | Fair Value Measurements Recurring [Member] | Fair Value Inputs Level2 [Member]
Fair value disclosure of assets		66,218,000
Short Term Investment [Member] | Fair Value Measurements Recurring [Member] | Fair Value Inputs Level3 [Member]
Fair value disclosure of assets

Stock Based Compensation (Detai

Stock Based Compensation (Details Narrative) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Restricted common stock, granted	376,625	376,625

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Option-Based Compensation Expenses (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Stock-based compensation expense included in operating expense	$ 1,826,000	$ 2,499,000	$ 5,607,000	$ 7,072,000
Tax benefit
Stock-based compensation expense, net of tax	1,826,000	2,499,000	5,607,000	7,072,000
Research And Development Expense [Member]
Stock-based compensation expense included in operating expense	972,000	1,012,000	3,013,000	2,756,000
Selling General And Administrative Expenses [Member]
Stock-based compensation expense included in operating expense	854,000	1,487,000	2,594,000	4,316,000
Restricted Stock [Member]
Stock-based compensation expense included in operating expense	98,000	348,000	172,000	516,000
Tax benefit
Stock-based compensation expense, net of tax	98,000	348,000	172,000	516,000
Restricted Stock [Member] | Research And Development Expense [Member]
Stock-based compensation expense included in operating expense	66,000	66,000		516,000
Restricted Stock [Member] | Selling General And Administrative Expenses [Member]
Stock-based compensation expense included in operating expense	$ 32,000	$ 282,000	$ 172,000

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Weighted-average Assumptions to Estimate the Fair Value of the Options Granted (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Payment Arrangement [Abstract]
Expected volatility	103.00%	109.00%	108.00%	109.00%
Expected term	6 years 2 months 30 days	5 years	5 years 1 month 2 days	5 years
Risk-free interest rate	1.83%	2.78%	2.21%	2.54%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Options Granted (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Payment Arrangement [Abstract]
Options granted	105,600	157,000	1,490,490	1,026,800
Weighted-average Exercise price	$ 2.58	$ 14.45	$ 6.53	$ 14.38
Weighted-average Grant date fair value	$ 2.09	$ 11.44	$ 5.14	$ 11.36

Operating Leases - Schedule of

Operating Leases - Schedule of Components of Lease Cost (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Leases [Abstract]
Operating lease cost	$ 434,000	$ 1,157,000
Variable lease cost	82,000	241,000
Short-term lease cost	$ 32,000	$ 113,000

Operating Leases - Schedule o_2

Operating Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Leases [Abstract]
2019, remainder	$ 422,000
2020	1,699,000
2021	1,713,000
2022	1,727,000
2023	1,741,000
Thereafter	3,667,000
Total undiscounted operating lease payments	10,969,000
Less: imputed interest	2,791,000
Total operating lease liabilities	8,178,000
Current portion of lease liability	1,696,000
Long-term lease liability	$ 6,482,000
Weighted-average remaining lease term for operating leases	76 months
Weighted-average discount rate for operating leases	9.60%